A prótese valvar cardíaca indiscutivelmente melhora a qualidade de vida e a sobrevida de pacientes com valvulopatias severas, mas a necessidade de uma terapia antitrombótica para prevenir complicações tromboembólicas promove grandes desafios aos clínicos e aos seus pacientes. Dos artigos pesquisados, a maioria foi composta de séries retrospectivas de casos ou de coortes históricas extraídas de banco de dados. Os raros estudos randomizados publicados não apresentaram poder estatístico para se avaliar o desfecho primário de morte ou evento tromboembólico. Neste artigo, optamos por realizar uma revisão sistemática da literatura, tentando responder a seguinte pergunta: qual a melhor estratégia antitrombótica nos três primeiros meses após implante de bioprótese valvar cardíaca (mitral e aórtica)? Após aplicar-se os critérios de extração por dois revisores, encontrou-se 1968 referências, selecionando-se 31 artigos (foram excluídos artigos truncados, que combinaram prótese mecânica, ou sem follow-up). Baseado nesta revisão de literatura, observou-se um baixo nível de evidência para qualquer estratégia terapêutica antitrombótica avaliada. Sendo assim, é interessante utilizar aspirina 75 a 100 mg/dia como estratégia antitrombótica após implante de bioprótese na posição aórtica, independente da etiologia, para pacientes sem outros fatores de risco, como fibrilação atrial ou evento tromboembólico anterior. Já para o implante de bioprótese na posição mitral, o risco de embolia, apesar de baixo, é mais relevante do que na posição aórtica, segundo as séries publicadas e coortes retrospectivas composta principalmente de pacientes idosos não reumáticos.
Hospital Ana Nery, Salvador, BA - Brasil
A prótese valvar cardíaca indiscutivelmente melhora a qualidade de vida e a sobrevida de pacientes com valvulopatias severas, mas a necessidade de uma terapia antitrombótica para prevenir complicações tromboembólicas promove grandes desafios aos clínicos e aos seus pacientes. Dos artigos pesquisados, a maioria foi composta de séries retrospectivas de casos ou de coortes históricas extraídas de banco de dados. Os raros estudos randomizados publicados não apresentaram poder estatístico para se avaliar o desfecho primário de morte ou evento tromboembólico. Neste artigo, optamos por realizar uma revisão sistemática da literatura, tentando responder a seguinte pergunta: qual a melhor estratégia antitrombótica nos três primeiros meses após implante de bioprótese valvar cardíaca (mitral e aórtica)?
Após aplicar-se os critérios de extração por dois revisores, encontrou-se 1968 referências, selecionando-se 31 artigos (foram excluídos artigos truncados, que combinaram prótese mecânica, ou sem
Baseado nesta revisão de literatura, observou-se um baixo nível de evidência para qualquer estratégia terapêutica antitrombótica avaliada. Sendo assim, é interessante utilizar aspirina 75 a 100 mg/dia como estratégia antitrombótica após implante de bioprótese na posição aórtica, independente da etiologia, para pacientes sem outros fatores de risco, como fibrilação atrial ou evento tromboembólico anterior. Já para o implante de bioprótese na posição mitral, o risco de embolia, apesar de baixo, é mais relevante do que na posição aórtica, segundo as séries publicadas e coortes retrospectivas composta principalmente de pacientes idosos não reumáticos.
A cardiopatia reumática crônica (CRC) é responsável por no mínimo 200 a 250 mil mortes prematuras a cada ano e é a maior causa de morte cardiovascular entre crianças e adultos jovens em países em desenvolvimento1 A prótese valvar cardíaca (PVC) indiscutivelmente melhora a qualidade de vida e a sobrevida de pacientes com valvulopatias severas, mas a necessidade de uma terapia antitrombótica para prevenir possíveis complicações tromboembólicas promove grandes desafios aos clínicos e aos seus pacientes2.
Desde o início de sua utilização na década de 60 do século passado, as biopróteses surgiram com a expectativa de substituição das próteses metálicas existentes, em virtude de não apresentarem teoricamente a necessidade da anticoagulação oral permanente, fato justificado pela sua composição tecidual preponderante, reduzindo assim a trombogenicidade elevada das próteses anteriores. Entretanto, essas biopróteses exibiam um grande ponto negativo: uma durabilidade relativamente curta (média de 10 a 15 anos), ocasionada por uma deterioração estrutural precoce, que acarretava a necessidade de reoperações, o que, consequentemente, incrementaria a morbimortalidade3.
As recomendações sumárias dos principais consensos internacionais2,4,5 sobre terapia antitrombótica após implante de bioprótese demonstram um baixo nível de evidência - "Grau C", fato justificado pela ausência de ensaios clínicos randomizados, e escassez de coortes prospectivas representativas das variadas terapias existentes, gerando uma grande variação nas condutas entre os diversos serviços. No Brasil a principal causa de doença valvar em crianças, adolescentes e adultos jovens é a CRC, levando a um elevado custo social e econômico6. Apesar desse fato, não é do conhecimento dos autores desta revisão qualquer estudo na literatura médica que tivesse abordado de maneira específica pacientes com CRC em relação a alguma estratégia antitrombótica no pós-operatório de implante de PVC.
Fora isto, a CRC tem uma relação direta com pobreza e más condições de saúde6, gerando um círculo vicioso de faringoamigdalites de repetição, reação imunológica cruzada, acometimento valvar cardíaco, sequelas debilitantes, cirurgia cardíaca numa idade economicamente ativa, custos para o sistema de saúde e para sociedade. Neste artigo, optamos por realizar uma revisão sistemática da literatura tentando responder a seguinte pergunta: qual a melhor estratégia terapêutica antitrombótica nos três meses inicias após implante de bioprótese valvar cardíaca?
Os bancos de dados do Medline, Embase, Cochrane e Scielo foram revisados entre o período de 1970 e 2012. Os termos ou palavras-chave utilizadas foram:
Foram excluídos artigos que abordassem de maneira conjunta ou isolada pacientes com prótese metálica, artigos sem resumo, ou ainda, artigos com metodologia incompleta ou confusa, não permitindo uma identificação de um grupo em terapia, e um grupo controle.
Utilizando a metodologia citada, foram encontradas 1.968 referências. Destas, após aplicar os critérios de extração, foram selecionados 31 artigos. Encontraram-se apenas três estudos randomizados com uma população total de 472 pacientes, em que foram testados níveis diferentes de anticoagulação, ou uso de varfarina (VAR)
A maioria dos artigos pesquisados foi composta de séries retrospectivas de casos ou de coortes históricas extraídas de banco de dados. Os raros estudos randomizados publicados não apresentaram poder estatístico para se avaliar o desfecho primário de morte ou evento tromboembólico. O uso de terapias antitrombóticas variadas como aspirina (ASA), triflusal, ticlopidina ou VAR, de modo isolado ou combinado, dificultou uma sistematização dos dados para realização de uma análise conjunta mais homogênea. Foi optado por dividir os estudos de acordo com a estratégia terapêutica principal a fim de facilitar a análise dos resultados.
Na
Desse modo, a incidência de eventos tromboembólicos sem terapia específica variou de 0,011 a 0,900 e 0,01 a 2,3%/pessoa-ano, quando avaliado a BPA e a BPM, respectivamente. Isto para um seguimento que variou de 6 a 120 meses, envolvendo publicações do ano de 1979 a 1995, conforme
Em relação à comparação entre VAR e ASA de forma isolada ou combinada, para pacientes que fizeram implante de BPA, constatou-se uma incidência de eventos tromboembólicos de 0,8 a 4,8%/pessoa-ano e de 0,6 a 3,9%/pessoa-ano, respectivamente. Mais recentemente, Brennan e cols.7 evidenciaram, através de uma coorte retrospectiva com grande tamanho amostral (25.656 pacientes), ser esta incidência de 1%/pessoa-ano para qualquer uma das terapias citadas.
Para aqueles que fizeram implante de BPM, Louagie e cols.8 constataram uma baixa incidência de eventos tromboembólicos (0,5 e 1,3%/pessoa-ano) comparando-se VAR e ASA, respectivamente. Entretanto, há coortes retrospectivas com uma incidência bem mais elevada, chegando a níveis de 55%/pessoa-ano nos primeiros 10 dias, conforme Heras e cols.9 constataram em 1995. No mesmo ano, Orszulak e cols.10 evidenciaram uma incidência de 40% nos primeiros 30 dias de pós-operatório. Por fim, mais recentemente, em 2013, num artigo ainda
As recomendações atuais para terapia antitrombótica nos três meses iniciais após implante de bioprótese valvar apresentam um baixo nível de evidência, como foi constatado nos estudos selecionados neste artigo. A
A Diretriz Brasileira de Valvulopatias - SBC 201138, recomenda como Classe I e nível de evidência C, o implante de bioprótese em pacientes que apresentem contraindicação ao uso de antagonistas da vitamina K (AVK), e o uso destes em pacientes com fibrilação atrial (Classe I e nível de evidência B), ou ainda, nos três meses iniciais após implante de bioprótese (Classe Iib e nível de evidência B), não especificando se na posição aórtica e/ou mitral.
Em relação aos pacientes com implante de BPA isolada, Brennan e cols.7, como já citado, publicaram uma expressiva coorte retrospectiva composta essencialmente de pacientes idosos. Neste estudo, os autores avaliaram três estratégias antitrombóticas (VAR, ASA ou ambas) e constataram uma incidência de embolia similar entre o grupo VAR e o grupo ASA isolados (1%/pessoa-ano), ocorrendo redução significativa de eventos embólicos apenas quando do uso simultâneo de ASA e VAR: 0,6%/pessoa-ano, com número de pacientes necessário a tratar (NNT) de 212, benefício que foi contrabalançado por um incremento na taxa de sangramento de quase 3 vezes, com número necessário para causar prejuízo (NNH) de 55, sendo em sua maior parte, segundo os autores, sangramento gastrointestinal, sem incremento em sangramento para o sistema nervoso central.
Em relação aos pacientes que fizeram implante de BPM, isolada ou combinada com implante de BPA, o trabalho mais citado na literatura ainda é o de Heras e cols.9 publicado em 1995, tendo se tornando uma importante referência negativa na literatura. Foi um estudo retrospectivo, observacional, com dados extraídos do serviço de cardiologia da Clínica Mayo. Os autores evidenciaram nesta coorte histórica uma elevada incidência de eventos embólicos nos primeiros 90 dias, sendo de 55%/pessoa-ano nos primeiros 10 dias, e de 10%/pessoa-ano entre 10 e 90 dias de pós-operatório. Em análise univariada, foi observado uma redução de 3.9% para 2.5% na incidência de embolia com uso de VAR. Ao analisar-se a taxa linear de embolia neste mesmo trabalho, notou-se que o benefício da redução de eventos com a anticoagulação foi significativo nos primeiros 10 dias, não havendo diferença estatística ou sequer numérica clara no período de 10 a 90 dias de pós-operatório. Ainda em 1995, Orszulak e cols10 constataram em outra coorte retrospectiva observacional, uma elevada incidência de eventos tromboembólicos - que chegou a 40% nos primeiros 30 dias, no mesmo cenário. Estes resultados desanimadores podem ter desestimulado a realização de estudos já que parecia clara a necessidade do uso de VAR nos meses iniciais de pós-operatório, principalmente após implante de BPM. Atualmente é notória essa lacuna quanto a real incidência de eventos embólicos após implante das modernas próteses biológicas, principalmente em pacientes portadores de CRC, e a definição da melhor estratégia antitrombótica.
Com esta escassez de estudos de impacto, justifica-se o baixo nível de evidência presente na diretriz brasileira e nos consensos internacionais. A maior parte dos estudos relatados representam experiências individuais de serviços de referência em cirurgia cardíaca, realizados no século passado, durante uma fase natural de desenvolvimento tecnológico das próteses, diferente em vários aspectos dos dispositivos prostéticos valvares atuais - teoricamente menos trombogênicos.
Como já dito, as biopróteses apresentam uma grande vantagem em relação às próteses mecânicas, que é a não obrigatoriedade do uso contínuo dos anticoagulantes, em geral, os AVK. Porém, várias circunstâncias clínicas fazem elevar a probabilidade de um evento embólico no pós-operatório, mesmo em portadores dessas próteses, desafiando o clínico e o paciente envolvido em escolher a melhor estratégia antitrombótica (AVK ou ASA, isolados ou combinados). Leva-se em consideração sempre os prós e contras de tal conduta, devido também à dificuldade de manejo dessas drogas pela necessidade do controle regular da razão normalizada internacional (RNI), já interfere diretamente no risco de sangramento agregado por este tipo de medicamento. Os pacientes portadores de CRC encontram-se em geral numa zona de baixo nível socioeconômico, dificultando em muito o manejo dos AVK.
É interessante ainda notar que os pacientes acometidos por essa patologia são diferentes do grupo acometido por valvulopatias degenerativas ou senis, mais prevalentes nos países desenvolvidos. Os primeiros (portadores de CRC) são em geral mais jovens e, assim, apresentam uma menor probabilidade clínica de cursarem com outras comorbidades que sabidamente elevam o risco cardioembólico, como a disfunção ventricular esquerda grave, fibrilação atrial, evento embólico prévio. Já em relação aos últimos, são em geral pacientes idosos e comumente portadores de outras patologias ou fatores de risco, compatíveis com o próprio envelhecimento, como por exemplo a hipertensão arterial, diabetes e fibrilação atrial, o que ocasiona incremento inevitável no risco cirúrgico para morte e para complicações, assim como maior probabilidade de eventos embólicos durante o seguimento clínico do pós-operatório, e risco ainda maior de sangramento durante a terapia anticoagulante instituída.
Em síntese, a melhor estratégia antitrombótica a ser adotada nos três meses iniciais após implante de BPA e BPM é baseada principalmente na experiência de cada serviço, e na opinião de especialistas - justificando o nível C de evidência - devido à escassez de estudos prospectivos e de ensaios clínicos randomizados. Para BPA o uso de ASA é similar ao uso de VAR em idosos, e para BPM permanece uma tendência mundial ao uso de VAR nos três meses iniciais. Pacientes portadores de CRC não foram devidamente estudados até a presente data.
Concepção e desenho da pesquisa: Durães AR; Obtenção de dados: Durães AR, Durães MAO; Análise e interpretação dos dados: Durães AR, Durães MAO, Correia LC, Aras Junior R; Redação do manuscrito: Durães AR, Durães MAO, Aras Junior R; Revisão crítica do manuscrito quanto ao conteúdo intelectual: Correia LC, Aras Junior R.
Declaro não haver conflito de interesses pertinentes.
O presente estudo não teve fontes de financiamento externas.
Este artigo é parte de tese de Doutorado de André Rodrigues Durães pela Universidade Federal da Bahia.
1. Marijon E, Mirabel M, Celermajer DS, Jouven X. Rheumatic heart disease.
2. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Barón-Esquivias G, Baumgartner H, et al. tGuidelines on the management of valvular heart disease (version 2012): The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg. 2012;42(4):S1-44.
3. Nowell J, Wilton E, Markus H, Jahanngiri M. Antithrombotic therapy following bioprosthetic aortic valve replacement. Eur J Cardiothorac Surg. 2007;31(4):578-85.
4. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr., Faxon DP, Freed MD. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.
5. Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH,American College of Chest Physicians. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
6. Barbosa PJB, Müller RE, Latado AL, Sociedade Brasileira de Cardiologia. Sociedade Brasileira de Pediatria. Sociedade Brasileira de Reumatologia. Diretrizes brasileiras para diagnóstico, tratamento e prevenção da febre reumática. Arq Bras Cardiol.2009;93(3 supl.4):1-18.
7. Brennan JM, Edwards FH, Zhao Y , O Brien'S, Booth ME, Dokholyan RS, et al. Early anticoagulation of bioprosthetic aortic valves in older patients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database. J Am Coll Cardiol. 2012; 60(11):971-7.
8. Louagie YA, Jamart J,
9. Heras M, Chesebro JH, Fuster V, Penny WJ, Grill DE, Bailey KR, et al. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol. 1995;25(5):1111-9.
10. Orszulak TA, Schaff HV, Pluth JR , Danielson GK, Riga FJ, Jestrup DM, et al.The risk of stroke in the early postoperative period following mitral valve replacement. Eur J Cardiothorac Surg. 1995;9(11):615-9.
11. Duraes AR, Duraes MAO, Correia LC , Fernandes MAS, Aras Jr R. Impact of aspirin use on the incidence of thromboembolic events after bioprosthesis replacement in patients with rheumatic disease. Rev Bras Cir Cardiovasc. 2013; (ahead of print)).
12. Cohen LH, Koster JK, Mee RB, Collins JJ Jr. Long-term follow-up of the Hancock bioprosthetic heart valve: a 6-year review. Circulation. 1979; 60(2 Pt 2):87-92.
13. Fuster V, Pumphrey CW, McGoon MD, Chesebra JH, Pluth JR, McGoon DC, et al. Systemic thromboembolism in mitral and aortic Starr-Edwards prostheses: a 10-19 year follow-up. Circulation. 1982;66(Pt 2):1157-61.
14. Ionescu MI, Smith DR, Hasan SS, Chidambaram M, Tandon AP. Clinical durability of the pericardial xenograft valve: ten years experience with mitral replacement. Ann Thorac Surg. 1982;34(3):265-77.
15. Cohn LH. The long-term results of aortic valve replacement. Chest. 1984;85(3):387-96.
16. Joyce LD, Nelson RM. Comparison of porcine valve xenografts with mechanical prostheses. A 7 1/2 year experience. J Thorac Cardiovasc Surg. 1984;88(1):102-13.
17. Gallo I, Artinano E, Nistal F. Four- to seven-year follow-up of patients undergoing Carpentier-Edwards porcine heart valve replacement. Thorac Cardiovasc Surg. 1985;3(6)3:347-51.
18. Hartz RS, Fisher EB, Finkelmeier B, De Boer A, Sanders JH Jr, Moran JM, et al. An eight-year experience with porcine bioprosthetic cardiac valves. J Thorac Cardiovasc Surg. 1986;91(6):910-7.
19. Gonzalez-Lavin L, Amini S, Gonzalez-Lavin J, McGrath LB, Fernandez J, Graf D. Instantaneous risk of events following aortic valve replacement with pericardial valves: a ten-year experience. Tex Heart Inst J. 1988;15(1):31-4.
20. Braile DM, Ardito RV, Greco OT, Lorga AM. IMC bovine pericardial valve: 11 years. J Card Surg. 1991;6(4 Suppl):580-8.
21. Babin-Ebell J, Schmidt W, Eigel P, Elert O. Aortic bioprosthesis without early anticoagulation--risk of thromboembolism. Thorac Cardiovasc Surg. 1995;43(4):212-4.
22. Orszulak TA, Schaff HV, Mullany CJ , Anderson BJ, Ilstrup DM, Puga FJ, et al.Risk of thromboembolism with the aortic Carpentier-Edwards bioprosthesis. Ann Thorac Surg. 1995;59(2):462-8.
23. Blair KL, Hatton AC, White WD, Smith LR, Lowe JE, Wolfe WG, et al. Comparison of anticoagulation regimens after Carpentier-Edwards aortic or mitral valve replacement. Circulation. 1994;90(5Pt 2):214-9.
24. Aramendi JL, Agredo J, Llorente A, Lavirarte C, Pijoan J. Prevention of thromboembolism with ticlopidine shortly after valve repair or replacement with a bioprosthesis. J Heart Valve Dis. 1988;7(6):610-4.
25 Gherli T, Colli A, Fragnito C, Nicolini F, Borrello B, Saccani S, et al. Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study. Circulation. 2004;110(5):496-500.
26. Ramos AI, Magalhaes HM, Maldonado M, Togna DJ, Meneghelo ZM, Arnoni AS, et al. Incidence of intracardiac thrombus and thromboembolism in the first three months after bioprosthetic valve implantation. Arq Bras Cardiol. 2004;83 (Spec N.):46-52.
27. Aramendi JI, Mestres CA, Martinez-Leon J, Campos V, Munoz G, Navas C. Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (trac): prospective, randomized, co-operative trial. Eur J Cardiothorac Surg. 2005;27(5):854-60.
28. Sundt TM, Zehr KJ, Dearani JA, Daly RC, Mullany CJ, McGregor CG, et al.Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement? J Thorac Cardiovasc Surg. 2005;129(5):1024-31.
29. Colli A, Mestres CA, Castella M , Gherli T. Comparing warfarin to aspirin (WoA) after aortic valve replacement with the St. Jude Medical Epic heart valve bioprosthesis: results of the WoA Epic pilot trial. J Heart Valve Dis. 2007;16(6):667-71.
30. Jamieson WR, Moffatt-Bruce SD, Skarsgard P, Hadi MA, Ye J, Fradet GJ, et al. Early antithrombotic therapy for aortic valve bioprostheses: is there an indication for routine use? Ann Thorac Surg. 2007;83:549-56.
31. Colli A, D'Amico R, Mestres CA, Pomar JL, Camara ML, Ruyra X, et al. Is early antithrombotic therapy necessary after tissue mitral valve replacement? J Heart Valve Dis. 2010;19(4):405-11.
32. ElBardissi AW, DiBardino DJ, Chen FY , Yamashita MH, Cohn LH. Is early antithrombotic therapy necessary in patients with bioprosthetic aortic valves in normal sinus rhythm? J Thorac Cardiovasc Surg.139(5):1137-45.
33. Gonzalez-Lavin L, Tandon AP, Chi S , Blair TC, McFaddon PM, Lewis B, et al. The risk of thromboembolism and hemorrhage following mitral valve replacement. A comparative analysis between the porcine xenograft valve and Ionescu-Shiley bovine pericardial valve. J Thorac Cardiovasc Surg. 1984;87(3):340-51.
34. Turpie AG, Gunstensen J, Hirsh J , Nelson H, Gent M. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet. 1988;1(8597):1242-5.
35. Goldsmith I, Lip GY, Mukundan S, Rosin MD. Experience with low-dose aspirin as thromboprophylaxis for the Tissuemed porcine aortic bioprosthesis: a survey of five years' experience. J Heart Valve Dis. 1998;7(5):574-9.
36. Moinuddeen K, Quin J, Shaw R , Dewar M, Tellides G, Kopf G, et al. Anticoagulation is unnecessary after biological aortic valve replacement. Circulation. 1998;98(Suppl.19);II95-8.
37. Brueck M, Kramer W, Vogt P, Steinert N, Roth P, Gorlach G, et al. Antiplatelet therapy early after bioprosthetic aortic valve replacement is unnecessary in patients without thromboembolic risk factors. Eur J Cardiothorac Surg. 2007;32(1):108-12.
38. Tarasoutchi F, Montera MW, Grinberg M, Barbosa MR, Piñeiro DJ, Sánchez CRM; et al. Sociedade Brasileira de Cardiologia. Diretriz brasileira de valvopatias - SBC 2011 / I Diretriz Interamericana de Valvopatias - SIAC 2011. Arq Bras Cardiol. 2011;97(5 supl. 1):1-67.
Andre Rodrigues Duraes Rua Alberto Silva, 439, Itaigara CEP 41815-000, Salvador, BA - Brasil E-mail:
Artigo recebido em 27/02/13; revisado em 10/06/13; aceito em 02/07/13.
Heart valve prosthesis unquestionably improve quality of life and survival of patients with severe valvular heart disease, but the need for antithrombotic therapy to prevent thromboembolic complications is a major challenge to clinicians and their patients. Of the articles analyzed, most were retrospective series of cases or historical cohorts obtained from the database. The few published randomized trials showed no statistical power to assess the primary outcome of death or thromboembolic event. In this article, we decided to perform a systematic literature review, in an attempt to answer the following question: what is the best antithrombotic strategy in the first three months after bioprosthetic heart valve implantation (mitral and aortic)? After two reviewers applying the extraction criteria, we found 1968 references, selecting 31 references (excluding papers truncated, which combined bioprosthesis with mechanical prosthesis, or without follow-up). Based on this literature review, there was a low level of evidence for any antithrombotic therapeutic strategy evaluated. It´s therefore interesting to use aspirin 75 to 100 mg / day as antithrombotic strategy after bioprosthesis replacement in the aortic position, regardless of etiology, for patients without other risk factors such as atrial fibrillation or previous thromboembolic event. In the mitral position, the risk of embolism, although low, is more relevant than in the aortic position, according to published series and retrospective cohorts comprised mostly of elderly non-rheumatic patients.
Hospital Ana Nery, Salvador, BA - Brazil
Heart valve prosthesis unquestionably improve quality of life and survival of patients with severe valvular heart disease, but the need for antithrombotic therapy to prevent thromboembolic complications is a major challenge to clinicians and their patients. Of the articles analyzed, most were retrospective series of cases or historical cohorts obtained from the database. The few published randomized trials showed no statistical power to assess the primary outcome of death or thromboembolic event. In this article, we decided to perform a systematic literature review, in an attempt to answer the following question: what is the best antithrombotic strategy in the first three months after bioprosthetic heart valve implantation (mitral and aortic)?
After two reviewers applying the extraction criteria, we found 1968 references, selecting 31 references (excluding papers truncated, which combined bioprosthesis with mechanical prosthesis, or without follow-up).
Based on this literature review, there was a low level of evidence for any antithrombotic therapeutic strategy evaluated. It´s therefore interesting to use aspirin 75 to 100 mg / day as antithrombotic strategy after bioprosthesis replacement in the aortic position, regardless of etiology, for patients without other risk factors such as atrial fibrillation or previous thromboembolic event. In the mitral position, the risk of embolism, although low, is more relevant than in the aortic position, according to published series and retrospective cohorts comprised mostly of elderly non-rheumatic patients.
The current evidence is limited to have a consistent and safe level of evidence regarding the best therapeutic strategy. Based on these studies, 75 to 100 mg/day of aspirin is interesting as antithrombotic strategy after implantation of aortic bioprosthesis, regardless of etiology, for patients with no other risk factors such as atrial fibrillation or previous thromboembolic event. As for mitral bioprosthesis, the risk of embolism, although low, is more relevant than in the aortic position, according to published series and retrospective cohorts - usually elderly non rheumatic patients.
The chronic rheumatic heart disease (CRHD) is responsible for at least 200 to 250 thousand premature deaths each year and is the leading cause of cardiovascular death among children and young adults in developing countries1. Heart valve prosthesis (HVP) unquestionably improve quality of life and survival of patients with severe valvular heart disease, but the need for antithrombotic therapy to prevent possible thromboembolic complications remain a major challenge to clinicians and their patients2.
Since the beginning of its use in the 60s, the bioprosthesis emerged with the expectation of replacing existing metal prosthesis, due to not theoretically requiring permanent oral anticoagulation, a fact justified by their predominant tissue composition, thereby reducing the high thrombogenicity of the prosthesis used until then. However, these prosthesis had a significant negative point: relatively short durability (mean 10-15 years), caused by early structural deterioration that resulted in the need for reoperations, which, in turn, would increase morbidity and mortality3.
The recommendations of the main international consensuses2,4,5 on antithrombotic therapy after bioprosthesis implantation demonstrate a low level of evidence (Grade C), which may be explained by the lack of randomized trials and scarcity of prospective cohorts representing current diverse therapies, generating considerable variation in behavior between the different services. In Brazil, the main cause of valve disease in children, adolescents and young adults is the CRHD, leading to a high social and economic cost6. In spite of that, the authors of this review do not know any study in the literature that have specifically addressed patients with CRHD in relation to any antithrombotic strategy in the postoperative period of HVP implantation.
Moreover, CRHD has a direct association with poverty and poor health6, creating a vicious circle of recurrent pharyngotonsillitis, crossed immune reaction, heart valve involvement, debilitating sequelae, cardiac surgery at an economically active age, costs to the health system and society. In this article, we decided to perform a systematic review of the literature in an attempt to answer the following question: what is the best antithrombotic therapy strategy in the first three months after implantation of bioprosthetic heart valve?
The Medline, Embase, Cochrane and SciELO databases were reviewed regarding the period between 1970 and 2012. The terms or keywords used were: heart valve prosthesis, bioprosthesis, aspirin or anticoagulants or thromboembolism and bioprosthesis. The search was limited to articles written in English or Portuguese and that referred to humans. The articles identified were assessed by two reviewers. Inclusion criteria were: original articles in English or Portuguese, prospective or retrospective, observational or intervention design, preferably having a control group and sample size > 19 patients.
Articles that included patients with metal prosthesis (alone or in conjunction), articles without abstracts, or articles with incomplete or confusing methodology, not allowing identification of a therapy group, and a control group were excluded.
Using the aforementioned methodology, 1,968 references were found. Of these, after applying the extraction criteria, 31 articles were selected. Found there were only three randomized studies with a total population of 472 patients, in whom different levels of anticoagulation or warfarin (WAR) versus antiplatelet agents were tested. Moreover, two prospective observational studies were found, resulting in a sample of 433 patients. The remaining studies were retrospective and several addressed the combined implantation of bioprosthesis in the aortic position (BAP) and bioprosthesis in the mitral position (BMP). No study had found a sample that was specific or predominant for patients with CRHD.
Most of the selected articles consisted of retrospective series or historical cohorts extracted from databases. The few published randomized trials showed no statistical power to assess the primary outcome of death or thromboembolic event. The use of several antithrombotic therapies, such as aspirin (ASA), triflusal, ticlopidine or WAR, isolated or combined, hindered data systematization to perform a more homogeneous joint analysis. We chose to divide the studies according to the main therapeutic strategy to facilitate result analysis.
Therefore, the incidence of thromboembolic events without any specific therapy ranged from 0.011 to 0.900 and 0.01 to 2.3% / person-year when evaluating ABP and MBP, respectively, for a follow up ranging from 6-120 months involving publications of the year 1979 to 1995, according to
Regarding the comparison between WAR and ASA, alone or in combination, for patients who had ABP implantation, there was an incidence of thromboembolic events of 0.8 to 4.8% / person-year and 0.6 to 3.9% / person-year, respectively. More recently, Brennan et al7 demonstrated, through a retrospective cohort study with large sample size (25,656 patients), that this is the incidence of 1%/person-year for any of the aforementioned therapies.
For those submitted to MBP implantation, Louagie et al8 found a low incidence of thromboembolic events (0.5 and 1.3%/person-year) when compared WAR and ASA, respectively. However, there are Retrospective with an incidence much higher, reaching levels of 55% / person-year in the first 10 days, as Heras et al9 found in 1995.
In the same year, Orszulak et al10 showed an incidence of 40% in the first 30 days postoperatively. Finally, more recently, in 2013, in an article still in press, Duraes et al11 prospectively analyzed a cohort of rheumatic patients in the first three postoperative months after mitral and/or aortic bioprosthetic implantation, showing a rare incidence of embolic events, regardless of being the aortic or mitral bioprosthesis, being even more sporadic in the latter, even when aspirin is compared with no antiplatelet agent, as shown in
Current recommendations for antithrombotic therapy in the first three months following bioprosthetic valve implantation have a low level of evidence, as observed in the studies selected for this article. The American Heart Association/American College of Cardiology (AHA/ ACC)4 recommend the use of ASA as class I and level of evidence C, alone or in combination with WAR (IIa / C), in accordance with the presence or not of some factor risk (atrial fibrillation, previous thromboembolic event, left ventricular dysfunction, and hypercoagulability state). The European Society of Cardiology (ESC)2 and the American College of Chest Physicians (ACCP)5 innovated by recommending the use of ASA (instead of WAR) when the replacement is performed in the aortic position only, keeping the use of the latter (WAR) for isolated or combined mitral position (IIa/C and II/C, respectively) based on recent studies focused on ABP implantation.
The Brazilian guideline of valve disease - SBC 201138 recommends as Class I and level C, bioprosthesis replacement in patients who have contraindications to the use of vitamin K antagonists (VKA), and use these drugs in patients with atrial fibrillation (Class I and level of evidence B), or within three months after initial implantation of a bioprosthesis (Class IIb and level of evidence B), not specifying whether in the aortic and / or mitral position.
Regarding patients with aortic replacement, Brennan et al7, as already mentioned, published an impressive retrospective cohort consisting mainly of elderly patients. In this study, the authors evaluated three antithrombotic strategies (WAR, ASA or both) and found an incidence of embolism similar between the WAR and the ASA alone group (1% / person-year), occurring significant reduction in embolic events only when using simultaneous ASA and WAR: 0.6% / person-year, with the number of patients needed to treat (NNT) of 212, benefit was offset by an increase in bleeding rate of almost 3-fold, with the number needed to harm (NNH) of 55, being for the most part, according to the authors, gastrointestinal bleeding with no increase in bleeding into the central nervous system.
Regarding patients with isolated or combined BMP, the most cited reference in the literature is still byHeras et al9 published in 1995, becoming an important negative paper. It was a retrospective and observational study, with database from the Mayo Clinic. The authors showed a high incidence of embolic events in the first 90 days, with 55%/person-year in the first 10 days, and 10%/person-year between 10 and 90 days, postoperatively. In univariate analysis, they observed a reduction of 3.9% to 2.5% in the incidence of embolism with WAR use. When analyzing the linear rate of embolism in this same work, it was observed that the benefit of reducing events with anticoagulation was significant in the first 10 days, with no statistical difference (even numerically) within 10 to 90 days postoperatively. In the same year, Orszulak et al10 found in another retrospective observational cohort, a high incidence of thromboembolic events - which reached 40% in the first 30 days in the same scenario. These disappointing results may have discouraged new studies since it seemed clear the need for the use of WAR in the first months after surgery, especially after implantation of BMP. Currently, there are doubts about the real incidence of embolism events after implantation of modern biological prosthesis, especially in patients with CRHD, and about the best antithrombotic strategy postoperatively. Thus, there is a large gap regarding the actual incidence of embolic events with current biological prosthesis, and there are no cohorts that specifically address individuals with CRHD following MBP and ABP implantation.
With this lack of impact studies justifies the low level of evidence the main internationals and Brazilian guidelines. Most studies reported represents individual experiences of referral services in cardiac surgery, performed in the last century, during a natural stage of technological development of prosthesis, different in many aspects of current valve prosthetic devices - theoretically less thrombogenic.
As already said, bioprosthesis have a great advantage over mechanical prosthesis, which is the exemption from continuous use of anticoagulants, in general, the AVK. However, several clinical circumstances do increase the probability of an embolic event postoperatively, even in patients with bioprosthesis, which is a challenge to the clinician and the patient involved in choosing the best antithrombotic strategy (VKA or ASA, alone or combined). This decision always takes into account the pros and cons of such conduct, also due to the difficulty in handling these drugs caused by the need for regular monitoring of the international normalized ratio (INR), which directly influences the risk of bleeding added by this type of drug. Patients with CRHD are generally from low socioeconomic level areas, difficult the management of VKA.
It is also noteworthy the fact that patients affected by this disease are different from the group affected by degenerative or senile valvular heart disease, more prevalent in developed countries. The first (patients with CRHD) are generally younger and thus less likely to have other comorbidities, which are known to increase cardioembolic risk, such as severe left ventricular dysfunction, atrial fibrillation and previous embolic event. Regarding the latter, they are generally elderly patients that commonly have other diseases or risk factors compatible with aging, such as arterial hypertension, diabetes and atrial fibrillation, which causes inevitable increase in surgical risk of death and complications, as well as greater probability of embolic events during follow-up after surgery and greater risk of bleeding during the instituted anticoagulant therapy.
In short, the best antithrombotic strategy to be adopted in the first three months after aortic and mitral replacement is based mainly on the experience of each service, and expert opinion - justify the level of evidence C - due to scarcity of prospective and randomized controlled trials. In BAP the use of ASA is similar to the use of WAR in the elderly patients, and in BMP remains a worldwide trend to WAR use. Patients with CRHD have not been adequately representative in previous studies to date.
Conception and design of the research: Durães AR; Acquisition of data: Durães AR, Durães MAO; Analysis and interpretation of the data: Durães AR, Durães MAO, Correia LC, Aras Junior R; Writing of the manuscript: Durães AR, Durães MAO, Aras Junior R; Critical revision of the manuscript for intellectual content: Correia LC, Aras Junior R.
No potential conflict of interest relevant to this article was reported.
There were no external funding sources for this study.
This article is part of the thesis of doctoral submitted by André Rodrigues Durães, from Universidade Federal da Bahia.
1. Marijon E, Mirabel M, Celermajer DS, Jouven X. Rheumatic heart disease.
2. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Barón-Esquivias G, Baumgartner H, et al. tGuidelines on the management of valvular heart disease (version 2012): The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg. 2012;42(4):S1-44.
3. Nowell J, Wilton E, Markus H, Jahanngiri M. Antithrombotic therapy following bioprosthetic aortic valve replacement. Eur J Cardiothorac Surg. 2007;31(4):578-85.
4. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr., Faxon DP, Freed MD. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.
5. Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH,American College of Chest Physicians. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
6. Barbosa PJB, Müller RE, Latado AL, Sociedade Brasileira de Cardiologia. Sociedade Brasileira de Pediatria. Sociedade Brasileira de Reumatologia. Diretrizes brasileiras para diagnóstico, tratamento e prevenção da febre reumática. Arq Bras Cardiol.2009;93(3 supl.4):1-18.
7. Brennan JM, Edwards FH, Zhao Y , O Brien'S, Booth ME, Dokholyan RS, et al. Early anticoagulation of bioprosthetic aortic valves in older patients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database. J Am Coll Cardiol. 2012; 60(11):971-7.
8. Louagie YA, Jamart J,
9. Heras M, Chesebro JH, Fuster V, Penny WJ, Grill DE, Bailey KR, et al. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol. 1995;25(5):1111-9.
10. Orszulak TA, Schaff HV, Pluth JR , Danielson GK, Riga FJ, Jestrup DM, et al.The risk of stroke in the early postoperative period following mitral valve replacement. Eur J Cardiothorac Surg. 1995;9(11):615-9.
11. Duraes AR, Duraes MAO, Correia LC , Fernandes MAS, Aras Jr R. Impact of aspirin use on the incidence of thromboembolic events after bioprosthesis replacement in patients with rheumatic disease. Rev Bras Cir Cardiovasc. 2013; (ahead of print)).
12. Cohen LH, Koster JK, Mee RB, Collins JJ Jr. Long-term follow-up of the Hancock bioprosthetic heart valve: a 6-year review. Circulation. 1979; 60(2 Pt 2):87-92.
13. Fuster V, Pumphrey CW, McGoon MD, Chesebra JH, Pluth JR, McGoon DC, et al. Systemic thromboembolism in mitral and aortic Starr-Edwards prostheses: a 10-19 year follow-up. Circulation. 1982;66(Pt 2):1157-61.
14. Ionescu MI, Smith DR, Hasan SS, Chidambaram M, Tandon AP. Clinical durability of the pericardial xenograft valve: ten years experience with mitral replacement. Ann Thorac Surg. 1982;34(3):265-77.
15. Cohn LH. The long-term results of aortic valve replacement. Chest. 1984;85(3):387-96.
16. Joyce LD, Nelson RM. Comparison of porcine valve xenografts with mechanical prostheses. A 7 1/2 year experience. J Thorac Cardiovasc Surg. 1984;88(1):102-13.
17. Gallo I, Artinano E, Nistal F. Four- to seven-year follow-up of patients undergoing Carpentier-Edwards porcine heart valve replacement. Thorac Cardiovasc Surg. 1985;3(6)3:347-51.
18. Hartz RS, Fisher EB, Finkelmeier B, De Boer A, Sanders JH Jr, Moran JM, et al. An eight-year experience with porcine bioprosthetic cardiac valves. J Thorac Cardiovasc Surg. 1986;91(6):910-7.
19. Gonzalez-Lavin L, Amini S, Gonzalez-Lavin J, McGrath LB, Fernandez J, Graf D. Instantaneous risk of events following aortic valve replacement with pericardial valves: a ten-year experience. Tex Heart Inst J. 1988;15(1):31-4.
20. Braile DM, Ardito RV, Greco OT, Lorga AM. IMC bovine pericardial valve: 11 years. J Card Surg. 1991;6(4 Suppl):580-8.
21. Babin-Ebell J, Schmidt W, Eigel P, Elert O. Aortic bioprosthesis without early anticoagulation--risk of thromboembolism. Thorac Cardiovasc Surg. 1995;43(4):212-4.
22. Orszulak TA, Schaff HV, Mullany CJ , Anderson BJ, Ilstrup DM, Puga FJ, et al.Risk of thromboembolism with the aortic Carpentier-Edwards bioprosthesis. Ann Thorac Surg. 1995;59(2):462-8.
23. Blair KL, Hatton AC, White WD, Smith LR, Lowe JE, Wolfe WG, et al. Comparison of anticoagulation regimens after Carpentier-Edwards aortic or mitral valve replacement. Circulation. 1994;90(5Pt 2):214-9.
24. Aramendi JL, Agredo J, Llorente A, Lavirarte C, Pijoan J. Prevention of thromboembolism with ticlopidine shortly after valve repair or replacement with a bioprosthesis. J Heart Valve Dis. 1988;7(6):610-4.
25 Gherli T, Colli A, Fragnito C, Nicolini F, Borrello B, Saccani S, et al. Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study. Circulation. 2004;110(5):496-500.
26. Ramos AI, Magalhaes HM, Maldonado M, Togna DJ, Meneghelo ZM, Arnoni AS, et al. Incidence of intracardiac thrombus and thromboembolism in the first three months after bioprosthetic valve implantation. Arq Bras Cardiol. 2004;83 (Spec N.):46-52.
27. Aramendi JI, Mestres CA, Martinez-Leon J, Campos V, Munoz G, Navas C. Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (trac): prospective, randomized, co-operative trial. Eur J Cardiothorac Surg. 2005;27(5):854-60.
28. Sundt TM, Zehr KJ, Dearani JA, Daly RC, Mullany CJ, McGregor CG, et al.Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement? J Thorac Cardiovasc Surg. 2005;129(5):1024-31.
29. Colli A, Mestres CA, Castella M , Gherli T. Comparing warfarin to aspirin (WoA) after aortic valve replacement with the St. Jude Medical Epic heart valve bioprosthesis: results of the WoA Epic pilot trial. J Heart Valve Dis. 2007;16(6):667-71.
30. Jamieson WR, Moffatt-Bruce SD, Skarsgard P, Hadi MA, Ye J, Fradet GJ, et al. Early antithrombotic therapy for aortic valve bioprostheses: is there an indication for routine use? Ann Thorac Surg. 2007;83:549-56.
31. Colli A, D'Amico R, Mestres CA, Pomar JL, Camara ML, Ruyra X, et al. Is early antithrombotic therapy necessary after tissue mitral valve replacement? J Heart Valve Dis. 2010;19(4):405-11.
32. ElBardissi AW, DiBardino DJ, Chen FY , Yamashita MH, Cohn LH. Is early antithrombotic therapy necessary in patients with bioprosthetic aortic valves in normal sinus rhythm? J Thorac Cardiovasc Surg.139(5):1137-45.
33. Gonzalez-Lavin L, Tandon AP, Chi S , Blair TC, McFaddon PM, Lewis B, et al. The risk of thromboembolism and hemorrhage following mitral valve replacement. A comparative analysis between the porcine xenograft valve and Ionescu-Shiley bovine pericardial valve. J Thorac Cardiovasc Surg. 1984;87(3):340-51.
34. Turpie AG, Gunstensen J, Hirsh J , Nelson H, Gent M. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet. 1988;1(8597):1242-5.
35. Goldsmith I, Lip GY, Mukundan S, Rosin MD. Experience with low-dose aspirin as thromboprophylaxis for the Tissuemed porcine aortic bioprosthesis: a survey of five years' experience. J Heart Valve Dis. 1998;7(5):574-9.
36. Moinuddeen K, Quin J, Shaw R , Dewar M, Tellides G, Kopf G, et al. Anticoagulation is unnecessary after biological aortic valve replacement. Circulation. 1998;98(Suppl.19);II95-8.
37. Brueck M, Kramer W, Vogt P, Steinert N, Roth P, Gorlach G, et al. Antiplatelet therapy early after bioprosthetic aortic valve replacement is unnecessary in patients without thromboembolic risk factors. Eur J Cardiothorac Surg. 2007;32(1):108-12.
38. Tarasoutchi F, Montera MW, Grinberg M, Barbosa MR, Piñeiro DJ, Sánchez CRM; et al. Sociedade Brasileira de Cardiologia. Diretriz brasileira de valvopatias - SBC 2011 / I Diretriz Interamericana de Valvopatias - SIAC 2011. Arq Bras Cardiol. 2011;97(5 supl. 1):1-67.
Andre Rodrigues Duraes Rua Alberto Silva, 439, Itaigara Postal Code 41815-000, Salvador, BA - Brazil E-mail:
Manuscript received February 27, 2013, revised manuscript June 10, 2013, accepted on 07/02/13.